Published: Dec 24, 2020
HYDERABAD, India, Dec. 24, 2020 /PRNewswire/ --
COVAXX's UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution
Agreement leverages Aurobindo's existing development, commercial and manufacturing infrastructure
Phase 2/3 clinical trials by COVAXX to begin early 1Q 2021 in Asia, Latin America and USA
Important step in ensuring equitable access and global supply during worldwide pandemic
Aurobindo Pharma Limited (NSE: AUROPHARMA) (BSE: 524804) (Reuters: ARBN.NS) (Bloomberg: ARBP:IN) and COVAXX, a US-based company, have entered into an Exclusive License Agreement to develop, commercialize and manufacture UB-612, the first Multitope Peptide-based Vaccine to fight COVID-19, for India and the United Nations Children's Fund (UNICEF) agency. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate.